Heart rate variability is related to disease severity in children and young adults with pulmonary hypertension by Latus, Heiner et al.
ORIGINAL RESEARCH
published: 07 July 2015
doi: 10.3389/fped.2015.00063
Edited by:
Maurice Beghetti,
University Hospitals of Geneva,
Switzerland
Reviewed by:
Anne Fournier,
Centre Hospitalier Universitaire
Sainte-Justine, Canada
Giorgia Grutter,
Pediatric Hospital Bambino Gesù,
Italy
*Correspondence:
Christian Apitz,
Pediatric Heart Center,
Justus-Liebig-University of Giessen,
Feulgenstr. 12, Giessen D-35392,
Germany
capitz@aol.com
†Heiner Latus and Dirk Bandorski
have contributed equally to this work.
Specialty section:
This article was submitted to Pediatric
Cardiology, a section of the journal
Frontiers in Pediatrics
Received: 18 February 2015
Accepted: 24 June 2015
Published: 07 July 2015
Citation:
Latus H, Bandorski D, Rink F,
Tiede H, Siaplaouras J, Ghofrani A,
Seeger W, Schranz D and Apitz C
(2015) Heart rate variability is related
to disease severity in children and
young adults with pulmonary
hypertension.
Front. Pediatr. 3:63.
doi: 10.3389/fped.2015.00063
Heart rate variability is related to
disease severity in children and
young adults with pulmonary
hypertension
Heiner Latus1†, Dirk Bandorski2†, Friederike Rink 1, Henning Tiede2, Jannos Siaplaouras1,
Ardeschir Ghofrani2, Werner Seeger 2, Dietmar Schranz1 and Christian Apitz1,3*
1 Pediatric Heart Centre, University Children’s Hospital Giessen, Giessen, Germany, 2 German Centre for Lung Research,
University of Giessen and Marburg Lung Centre, Giessen, Germany, 3 Department of Pediatric Cardiology, University Children’s
Hospital Ulm, Ulm, Germany
Background: Pulmonary hypertension (PH) is frequently associated with an increase in
sympathetic tone. This may adversely affect cardiac autonomic control. Knowledge about
the clinical impact of autonomic dysfunction in patients with PH is limited. We aimed to
assess whether parameters of heart rate variability (HRV) are related to disease severity
in children with PH.
Methods: Parameters of HRV [SDNN, standard deviation of normal-to-normal intervals
and SDANN, standard deviation of mean values for normal-to-normal intervals over 5min]
were determined from Holter electrocardiograms of 17 patients with PH without active
intracardial shunt (10 female, mean age 12.88.7 years). Patients were allocated to two
groups according to their disease severity: patients with moderate PH [ratio of pulmonary
to systemic arterial pressure (PAP/SAP ratio)<0.75] (n=11), patients with severe PH
(PAP/SAP ratio>0.75) (n=6). An additional group of five adolescents with Eisenmenger
syndrome (PAP/SAP ratio 1.130.36) was included.
Results: Children with severe PH had significantly lower values of HRV [SDNN
(73.821.1 vs. 164.938.1ms), SDANN (62.219.0 vs. 139.533.3ms)] compared
to patients with moderate PH (p=0.0001 for all). SDNN inversely correlated with
ratio of PAP/SAP of PH patients without shunt (r= 0.82; p=0.0002). Eisenmenger
patients showed no significant difference of HRV [SDNN 157.643.2ms, SDANN
141.245.3ms] compared to patients with moderate PH without shunt (p>0.05 for all).
Conclusion: According to our results, children with severe PH may have alterations in
HRV. Since HRV appears to be related to disease severity, it may therefore serve as an
additional diagnostic marker of PH. Remarkably, although Eisenmenger patients have
systemic pulmonary arterial pressures, they seem to have preserved HRV, which might
reflect a more favorable autonomic adaptation.
Keywords: heart rate variability, pulmonary hypertension, pediatrics, pediatric cardiology, Holter electrocardio-
gram, arrhythmias
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Introduction
Pulmonary hypertension (PH) is characterized by progressive
pulmonary vascular remodeling and consecutive elevation of pul-
monary vascular resistance and pressure, which may ultimately
result in right ventricular failure and death. Chronic right heart
failure is associated with an increase in sympathetic tone, which
may adversely affect cardiac autonomic control (1, 2). Little is
known about autonomic dysfunction in patients with PH. The
analysis of heart rate variability (HRV) as a marker of auto-
nomic dysfunction can be obtained from conventional Holter-
ECG recordings, which are frequently performed as part of the
routine care in pediatric cardiology. An abnormal HRV has been
shown in adults and children with pulmonary arterial hyperten-
sion (PAH) and seems to be associated with poor outcome (1–3).
An abnormal HRV has also been shown to be an independent
predictor of adverse prognosis in pediatric patients with different
forms of congenital heart disease (4–6).
Since PAH is a progressive disease and shows a high mortality,
despite new developments in the treatment of PAH in children (7),
markers of disease severity to identify patients at risk are required
and may provide early detection of clinical worsening or help to
guide medical therapy (8).
The aim of our study was therefore to assess whether sympa-
thetic parameters ofHRVare related to disease severity in children
with PH.
Patients and Methods
Seventeen patients with PH (10 female, mean age 12.8 8.7 years)
were included in this prospective study after written informed
consent was obtained. Twelve of the 17 patients had idiopathic
PAH, 3 patients had associated chronic lung disease, 2 had “out
of proportion” PH due to left heart disease (pulmonary vein
stenosis in one, and borderline left ventricle in another one). An
additional group of five adolescents with Eisenmenger syndrome
was studied. A cohort of 10 healthy children, adolescents, and
young adults (mean age 14.8 11.2 years; 6 females) served as a
control group.
Holter-ECG recording (CardioMem®CM 3000, GETEMED,
Teltow, Germany) was performed for 48 h during daily activities.
None of the patients had a history of palpitations or syncope.
Data were analyzed by an operator-controlled analysis software
package (CardioDay®, GETEMED, Teltow, Germany). Parameters
of HRV (SDNN, standard deviation of normal-to-normal inter-
vals, SDANN, standard deviation of mean values for normal-to-
normal intervals over 5min, rMSSD, square root of the mean
square differences of successive RR intervals, and pNN50, pro-
portion of the number of pairs of successive normal-to-normal
intervals that differ by more than 50ms divided by total num-
ber of normal-to-normal interval) were determined from the
recordings.
The clinical data obtained included WHO functional class,
echocardiographic assessment of tricuspid annular plane sys-
tolic excursion (TAPSE), and right atrial area indexed for body
surface area, and at cardiac catheterization, right atrial pres-
sure (RAP), mean pulmonary arterial pressure (mPAP), ratio of
mPAP to mean systemic arterial pressure (mSAP), pulmonary
capillary wedge pressure (PCWP), mixed venous oxygen sat-
uration (mixed venous sO2), cardiac index (CI) (using Fick
method), and pulmonary vascular resistance index (PVRI). Anal-
ysis of invasive hemodynamic data has been performed ret-
rospectively, time interval between cardiac catheterization and
Holter-ECG was 18 14months. Cardiac catheterization was
performed free-breathing under sedation with midazolam and
propofol.
Data from all the children were analyzed and then data from
those with moderate (defined as an mPAP/mSAP ratio of <0.75)
and severe PH (mPAP/mSAP ratio >0.75) were analyzed sepa-
rately. The study was approved by the local Ethics Committee.
Statistical Analysis
The data are presented as mean and SDs. Differences between
groups were examined for significance by the use of unpaired t-
test and non-parametric Mann–Whitney U-test as appropriate.
Correlations were tested using linear regression analysis. Analysis
was performed using GraphPad statistical software package (San
Diego, CA, USA). A p value 0.05 was considered statistically
significant.
Results
According to their disease severity, patients could be allocated to
two groups: (group 1) patients with moderate PH (mPAP/mSAP
ratio <0.75) (n= 11) and (group 2) patients with severe PH
(PAP/SAP ratio >0.75) (n= 6). There were no significant differ-
ences in age, time interval since diagnosis, height, weight, and
body surface area between both groups (Table 1). About 81% of
patients of group 1were inWHO functional class I and II, whereas
67% of patients in group 2 were in WHO functional class III and
IV. Idiopathic PAHwas the most frequent diagnosis (73 and 67%)
in both groups. All patients received PAH-specific medication, 13
patients as combination therapy. In addition, two patients (one of
each group) received digoxin, and one patient in group 2 was on
betablocker therapy.
Echocardiographic and Hemodynamic
Measurements
RV systolic function assessed by TAPSE was impaired (Z-
score< 2) in three patients in group 1 (27%) and five patients
in group 2 (83%), resulting in significantly worse TAPSE Z-score
in patients with severe PH ( 0.48 2.7 vs. 3.59 1.5; p= 0.02)
(Table 2). Patients with severe PH also had larger right atrial
dimensions assessed by right atrial area indexed for body surface
area compared to patients with mild PH.
Right atrial pressure was not elevated for the whole
group (5.4 2.9mmHg) and was not significantly different
between both subgroups. Mean PAP for all children was
48.4 17.3mmHg, mPAP/mSAP 0.62 0.26, and PVRI 14.0
7.9WUxm2, and all of these measures showed significant
differences between both subgroups. PCWP was significantly
higher in group 2 (11.8 2.6mmHg) compared to 7.1
3.0mmHg in group 1, which can be explained by the fact that
both patients with “out of proportion” PH due to left heart disease
were in group 2. CI and mixed venous sO2 was lower in group 2,
however, did not reach statistical significance (Table 2).
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TABLE 1 | Patient characteristics.
All patients PAP/SAP< 0.75 PAP/SAP> 0.75 Significance p
Age (years) 12:8 8:7 13:7 7:7 11:1 11:0 0:58
Time interval since diagnosis (months) 40:5 31:3 43:6 27:2 34:6 39:8 0:588
Height (cm) 132:8 36:3 143:9 28:2 112:3 43:0 0:086
Weight (kg) 36:3 26:1 42:6 26:7 24:9 22:6 0:19
BSA (m2) 1:13 0:6 1:28 0:5 0:86 0:6 0:14
WHO functional class (I/II/III/IV) 2/9/5/1 2/7/2/0 –/2/3/1
Gender (female/male) 10/7 6/5 4/2
Diagnosis IPAH n (of total) 12/17 8/11 4/6
PAH-specific medication (PDE5i/ERA/inhProstanoid/CCB) 14/8/2/4 8/4/2/4 6/4/0/0
Combination therapy (dual/triple) 13/0 9/0 4/0
Antiarrhythmic medication (BB/Digoxin) 1/2 0/1 1/1
PDE-5i, phosphodiesterase-5 inhibitor; ERA, endothelin receptor antagonist; CCB, calcium-channel-blocker; BB, betablocker; BSA, body surface area; WHO,World Health Organization.
TABLE 2 | Echocardiographic and hemodynamic measurements.
All
patients
PAP/SAP
< 0.75
PAP/SAP
> 0.75
Significance
p
TAPSE (Z-score)  1:64 2:7  0:48 2:7  3:59 1:5 0:02
RA-area/BSA 12:4 4:2 9:9 1:8 14:9 4:4 0:025
RAP (mmHg) 5:4 2:9 5:1 3:4 5:8 2:2 0:69
mPAP (mmHg) 48:4 17:3 39:2 12:4 63:7 13:2 0:002
mPAP/mSAP 0:62 0:26 0:47 0:15 0:91 0:18 0:0002
PCWP (mmHg) 8:9 3:6 7:1 3:0 11:8 2:6 0:006
Hb (g/dl) 12:6 2:2 12:6 2:6 12:7 1:7 0:92
Mixed venous
sO2 (%)
69:9 7:4 72:6 7:0 65:8 6:5 0:08
CI (l/min/m2) 3:9 1:2 4:1 1:2 3:7 1:3 0:56
PVRI (WUxm2) 14:0 7:9 10:5 5:4 21:1 7:8 0:008
TAPSE, tricuspid annular plane systolic excursion; RA, right atrium; BSA, body surface
area; RAP, right atrial pressure; mPAP, mean pulmonary arterial pressure; mSAP, mean
systemic arterial pressure; PCWP, pulmonary capillary wedge pressure; Hb, hemoglobin;
CI, cardiac index; venous sO2, venous oxygen saturation; PVRI, pulmonary vascular
resistance index.
Holter-ECG
Minimal heart rate (HR) was significantly higher in children
with severe PH (75.7 12.2 bpm) compared to children with
moderate PH (56.5 10.3 bpm) (p= 0.004). Mean HR was also
higher in patients of group 2 compared to group 1, but did not
reach statistical significance. In contrast, maximum HR tended
to be lower in patients of group 2 (Table 3). Children of group
2 had significantly lower values of HRV [SDNN (73.8 21.1
vs. 164.9 38.1ms), SDANN (62.2 19.0 vs. 139.5 33.3ms),
rMSSD (31.0 8.7 vs. 73.6 22.7ms), and pNN50 (5.8 3.4 vs.
28.0 8.8%)] compared to group 1 (p= 0.0001 for all).
While no differences in measures of HRV were found between
patients with moderate PH and the control group, all values of
HRV (SDNN, SDANN, rMSSD, and pNN50) were significantly
lower in patients with severe PH compared to healthy controls
(Table 3).
Arrhythmias
Supraventricular premature beats were recorded in five patients of
group 1 and two patients of group 2, whereas only two patients had
more than three premature beats per hour. There was no occur-
rence of atrial tachycardia or atrial flutter. Ventricular premature
beats were recorded in four patients of group 1 and one of group
2, whereas only one patient had more than three premature beats
per hour. There was no occurrence of higher degreed ventricular
arrhythmias. No relation between the occurrence of arrhythmias
and disease severity could be seen.
Correlations
There was no correlation between SDNN and TAPSE, as well as
indexed right atrial area. SDNN neither correlated with RAP, Hb,
mixed venous sO2, and CI (Table 4). However, SDNN correlated
inversely with mPAP (r= 0.71; p= 0.002), the ratio of PAP/SAP
(r= 0.82; p= 0.0002), PVRI (r= 0.59; p= 0.02), and PCWP
(r= 0.77; p= 0.0005) (Figure 1).
Eisenmenger Syndrome
Patients with Eisenmenger syndrome were significantly older
(25.1 5.2 years) compared to patients of group 1 and 2. All of
them were in WHO functional class II and III and all of them
were on PAH specific medications. Right ventricular function
was preserved (TAPSE Z-value  0.65) and indexed right atrial
area was 11.01 3.38 cm2/m2. RAP was 9.0 5.7mmHg, mPAP
91.3 30.6mmHg, ratio of mPAP/mSAP was 1.13 0.36 and
PVRI 33.8 15.9WUxm2.
Measures of HRV of patients with Eisenmenger syndrome
were SDNN 157.6 43.2ms, SDANN 141.2 45.3ms, rMSSD
66.8 16.0ms, and pNN50 18.0 11.6%, and were not signifi-
cantly different compared to patients of group 1 (moderate PH)
(p> 0.05 for all) (Figure 2).
All of the patients with Eisenmenger syndrome had ventricular
premature beats [four of them (80%) more than 3/h]. About 40%
of the patients had higher degreed ventricular arrhythmias, one
had couplets of premature ventricular beats, and another patient
had non-sustained ventricular tachycardia. One patient had fre-
quent supraventricular premature beats and a non-sustained
supraventricular tachycardia.
Discussion
The results of our presented study showed for the first time
that there is a strong relation between HRV and disease severity
in children with PH. Except for patients with the Eisenmenger
syndrome, HRV correlated with mPAP, mPAP/mSAP, PVRI, and
PCWP. HRV may therefore serve as an additional marker of
Frontiers in Pediatrics | www.frontiersin.org July 2015 | Volume 3 | Article 633
Latus et al. Heart rate variability in pulmonary hypertension
TABLE 3 | Holter monitoring data.
All patients PAP/SAP<0.75 PAP/SAP> 0.75 Significance p Control group Significance p*
Mean HR (bpm) 88:4 17:5 83:5 15:2 97:3 19:1 0:12 85:9 11:3 0.69; 0.15
Min HR (bpm) 63:3 14:2 56:5 10:3 75:7 12:2 0:004 58:8 12:7 0.86; 0.01
Max HR (bpm) 148:4 32:5 156:4 30:7 133:7 33:0 0:18 167:4 19:4 0.35; 0.02
SDNN (ms) 132:8 55:3 164:9 38:1 73:8 21:1 0:0001 181:1 43:9 0.39; 0.001
SDANN (ms) 112:2 47:5 139:5 33:3 62:2 19:0 0:0001 152:1 40:2 0.45; 0.0003
rmSSD (ms) 58:6 28:0 73:6 22:7 31:0 8:7 0:0001 75:1 34:5 0.91; 0.01
pNN50 (%) 20:2 13:1 28:0 8:8 5:8 3:4 0:0001 22:8 12:5 0.30; 0.008
PAP, pulmonary arterial pressure; SAP, systemic arterial pressure; HR, heart rate (per minute; min=minimum, max=maximum); SDNN, standard deviation of normal-to-normal intervals;
SDANN, standard deviation of mean values for normal-to-normal intervals over 5min; rMSSD, square root of the mean square differences of successive RR intervals; pNN50, proportion
of the number of pairs of successive normal-to-normal intervals that differ by more than 50ms divided by total number of normal-to-normal interval.
*p=PAP/SAP< 0.75 vs. controls; PAP/SAP>0.75 vs. controls.
TABLE 4 | Correlations with SDNN.
Correlation r Significance p
TAPSE (Z-score) 0:35 0:19
RA-area/BSA  0:49 0:11
RAP (mmHg)  0:37 0:19
mPAP (mmHg)  0:71 0:002
mPAP/mSAP  0:82 0:0002
PCWP (mmHg)  0:77 0:0005
Hb (g/dl) 0:05 0:86
Mixed venous sO2 (%) 0:42 0:11
CI (l/min/m2) 0:05 0:88
PVRI (WUxm2)  0:59 0:02
TAPSE, tricuspid annular plane systolic excursion; RA, right atrium; BSA, body surface
area; RAP, right atrial pressure; mPAP, mean pulmonary arterial pressure; mSAP, mean
systemic arterial pressure; PCWP, pulmonary capillary wedge pressure; Hb, hemoglobin;
CI, cardiac index; venous sO2, venous oxygen saturation; PVRI, pulmonary vascular
resistance index.
disease severity in children with PH without intracardiac shunt
to identify patients at risk, to detect early clinical worsening, and
to guide medical therapy.
There are different mechanisms discussed in the literature,
which may contribute to impaired HRV in patients with PH.
Stretching of the sinoatrial node may result in a reduction of
HRV (9). Children with severe PH in our study had significantly
larger right atriums than patients with moderate PH. Reduction
of SDNN and SDANN can also be explained by chronic increased
sympathetic nerve activity, which has been previously reported
in adult patients with PAH (10). In addition, down-regulation of
beta-adrenergic receptors has been shown to have impact onHRV
in left and right ventricular failure (11).
Previous authors were able to demonstrate an impact of
impaired left ventricular function on HRV (12) in patients with
idiopathic dilated cardiomyopathy (IDC). In our study, left ven-
tricular function was unimpaired in both subgroups. Further-
more, we were not able to demonstrate a relation between
HRV and right ventricular function (assessed by TAPSE) and
right atrial size (assessed by indexed right atrial area). Although
TAPSE values were lower in the subgroup with severe PH,
right ventricular function seemed to have no significant impact
on HRV.
Remarkably, minimal heart rate was significantly higher in
children with severe PH compared to children with moderate PH,
and also mean heart rate tended to be higher, which might be
a physiological response to achieve an adequate cardiac output
despite of imminent RV failure. However, those patients with
more accelerated heart rate may show a relevant shortening of
diastole, and thus, impaired ventricular filling during diastole,
which may result in progressive RV failure. β-Blockers may be
a reasonable treatment option of this condition. β-Blockers can
improve ventricular filling by decreasing heart rate and extending
the duration of diastole. Concern about the use of β-blockers
in PH was formerly based primarily on their potential to pro-
duce negative inotropic effects (13, 14). In animal models of PH,
the non-selective β-blocker carvedilol seemed to improve right
ventricular function and myocardial remodeling (15). However,
further clinical studies in adults and children with PH are clearly
needed.
The prevalence of serious supraventricular or ventricular
arrhythmias in our PH-patients was low, and there was no relation
of arrhythmias to disease severity. Previous studies on arrhyth-
mias in patients with PH were focused on adult patients, and
primarily revealed supraventricular arrhythmias (i.e., atrial flutter,
atrial fibrillation) often leading to clinical deterioration (16–18).
According to our results, supraventricular arrhythmias do not
seem to be a relevant finding in the pediatric population.
Of particular interest are also the results of our adolescent
patients with Eisenmenger syndrome. Eisenmenger patients are
known for theirmore physiological adaptation to right ventricular
afterload (19). As they have elevated pulmonary arterial pressures
since the first days of life, their right ventricles usually show a
remarkable hypertrophy, and right ventricular function is mostly
preserved, in contrast to patients with severe IPAH and simi-
lar levels of pulmonary pressure, who develop increased right
ventricular afterload later in life, which will frequently result in
right ventricular failure (20, 21). Our study results showed a
rather preserved HRV in patients with Eisenmenger syndrome
despite of their systemic PA pressures, which might also reflect
a more favorable autonomic adaptation. In contrast, remarkably
high was the prevalence of relevant arrhythmias in the Eisen-
menger group. This might be the reason for sudden cardiac
death being not uncommon in patients with Eisenmenger syn-
drome (22).
Study Limitations
The small number of patients studied and the heterogeneity of
the underlying etiology of PH may limit the interpretation of the
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FIGURE 1 | Correlations between the SD of normal-to-normal intervals (SDNN) and mean pulmonary arterial pressure (mPAP) (A), the ratio of mean
pulmonary arterial to systemic arterial pressure (mPAP/mSAP) (B), indexed pulmonary vascular resistance (PVRI) (C), and pulmonary capillary wedge
pressure (PCWP) (D).
FIGURE 2 | Standard deviation of normal-to-normal intervals (SDNN)
for patients with moderate PH (mPAP/mSAP ratio<0.75), patients
with severe PH (mPAP/mSAP ratio>0.75) and patients with the
Eisenmenger syndrome.
data. Although there was a longer time interval between the HRV
measurement and the invasive assessment of hemodynamics, the
patients’ clinical condition remained stable andmedical treatment
unchanged, suggesting that the severity of PH did not change
significantly during that time. While digoxin and beta blockers
are known to alter heart rate and myocardial inotropy, which may
affect the results of the HRV measurement, only three patients in
this study received such medication.
Conclusion
According to our results, children with severe PH may have
alterations in HRV. Since HRV appears to be related to disease
severity, it may therefore serve as an additional clinical marker
of disease in PH. Remarkably, patients with the Eisenmenger
syndrome seem to have preserved HRV despite of systemic
PA pressures, which might reflect a more favorable autonomic
adaptation.
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